{
    "organizations": [],
    "uuid": "e9a895f8d4a8991754dd5d5ffa767b811d982a44",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nicox-provides-2018-outlook-and-20/brief-nicox-provides-2018-outlook-and-2017-estimated-financial-results-idUSFWN1QO03H",
    "ord_in_thread": 0,
    "title": "BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - NICOX SA:\n* PROVIDES 2018 OUTLOOK AND 2017 ESTIMATED FINANCIAL RESULTS\n* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON\n* PIPELINE CANDIDATES MOVING TOWARDS CLINICAL DEVELOPMENT, WITH IND SUBMISSIONS TO THE U.S. FDA PLANNED FOR NCX 470 IN Q3 2018 AND NCX 4251 IN Q1 2019\n* ESTIMATED CASH POSITION OF â‚¬41.4 MILLION AS OF DECEMBER 31, 2017\n* IN 2018 WE ALSO EXPECT TO MAKE SIGNIFICANT ADVANCES IN OUR NO-DONATING RESEARCH PIPELINE - CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom:)\n ",
    "published": "2018-03-06T14:47:00.000+02:00",
    "crawled": "2018-03-07T19:21:16.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "nicox",
        "sa",
        "provides",
        "outlook",
        "estimated",
        "financial",
        "result",
        "zerviatetm",
        "cetirizine",
        "ophthalmic",
        "solution",
        "launch",
        "planned",
        "partner",
        "eyevance",
        "pharmaceutical",
        "fall",
        "allergy",
        "season",
        "pipeline",
        "candidate",
        "moving",
        "towards",
        "clinical",
        "development",
        "ind",
        "submission",
        "fda",
        "planned",
        "ncx",
        "q3",
        "ncx",
        "q1",
        "estimated",
        "cash",
        "position",
        "million",
        "december",
        "also",
        "expect",
        "make",
        "significant",
        "advance",
        "research",
        "pipeline",
        "ceo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}